Prostatilen is a bioregulatory peptide complex extracted from bovine prostate tissue, developed by the Khavinson group in Russia and used clinically in Eastern European countries since the 1990s. It exerts organotropic (organ-specific) effects on prostate tissue through anti-inflammatory, immunomodulatory, and microcirculation-enhancing mechanisms. Clinical studies spanning over 1,400 patients report a 96.7% response rate for chronic prostatitis symptoms. Prostatilen AC is an enhanced formulation containing zinc arginyl-glycinate for additional reproductive support.
Category: Bioregulator / Urological. Evidence rating: C (early/mixed human evidence).
Clinical status: Registered pharmaceutical preparation in Russia and Eastern Europe. Not studied in Western clinical trials.
Prostatilen contains short peptide fragments that exhibit organotropic activity toward prostate tissue. These peptides normalize the prooxidant-antioxidant balance, restore microcirculation in prostatic vasculature, and modulate local immune responses. The anti-inflammatory effect involves…
Safety considerations: Generally well-tolerated across 1,400+ patients studied; Minimal adverse effects reported in clinical trials; Injection site discomfort with IM administration.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | bioactive |
|---|---|
| Anti-doping status | not-listed |
| US regulatory status | Not FDA-approved. Not available as a pharmaceutical. |
Both are Khavinson-group bioregulatory peptides targeting the prostate, but they differ in composition. Prostatilen is extracted from bovine prostate tissue, while prostamax is a synthetic peptide bioregulator (Lys-Glu-Asp-Pro).
Available as intramuscular injection (5-10 mg daily for 5-10 days) or rectal suppositories (30 mg). Clinical effects typically begin after 2-3 injections with maximal benefit by day 5-6.
Prostatilen is a bioregulatory peptide complex extracted from bovine prostate tissue, developed by the Khavinson group in Russia and used clinically in Eastern European countries since the 1990s. It exerts organotropic (organ-specific) effects on prostate tissue through anti-inflammatory, immunomodulatory, and microcirculation-enhancing mechanisms. Clinical studies spanning over 1,400 patients…
On the PeptideAtlas A–F scale, Prostatilen is rated C (Early Evidence). Early human evidence, limited trials, or mixed findings
Registered pharmaceutical preparation in Russia and Eastern Europe. Not studied in Western clinical trials.